New Releases from NCBI BookshelfBaricitinib (Olumiant): Indication: For the treatment of adult patients with severe alopecia areata: CADTH Reimbursement Recommendation [Internet].​Baricitinib (Olumiant): Indication: For the treatment of adult patients with severe alopecia areata: CADTH Reimbursement Recommendation [Internet].

By /

CADTH recommends that Olumiant be reimbursed by public drug plans for the treatment of adults with severe alopecia areata (AA) if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top